• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $2 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-69 Mln

Athenex Inc. (ATNX) Share Price

$0.01

As on 26-Jul-2023 09:30 EST

up-down-arrow $0.00103.33%

  • Prev Close info

    $0.00

  • Day's Openinfo

    $0.00

  • Today's Highinfo

    $0.01

  • Today's Lowinfo

    $0.00

  • Today's Volumeinfo

    2,035

  • 52 Week rangeinfo

    $0.00 - 23.80

Please wait...

Athenex Inc. (ATNX) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Athenex (ATNX)
-99.79 -96.19 -99.47 -99.95 -97.00 -89.09 --
S&P BSE Healthcare*
9.99 2.62 14.24 60.65 18.50 20.32 12.34
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 26-Jul-2023  |  *As on 01-Mar-2024  |  #As on 26-Oct-2023
2022
2021
2020
2019
2018
Athenex (ATNX)
-89.12 -87.70 -27.57 20.33 -20.09
S&P Small-Cap 600
-17.42 25.27 9.57 20.86 -9.70
S&P BSE Healthcare
-12.10 20.87 61.45 -3.55 -5.89

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Athenex Inc. (ATNX) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Athenex Inc. (ATNX)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Athenex Inc. (ATNX)

        Chairman & CEO

        Dr. Yiu-Nam Lau F.R.C.P., M.B.B.S., M.D., Ph.D.

        COO & Pres of Athenex Pharmaceutical Division

        Mr. Jeffrey M. Yordon

        Headquarters

        Buffalo, NY

        FAQs for Athenex Inc. (ATNX)

        The total asset value of Athenex Inc. (ATNX) stood at $ 204 Mln as on 31-Dec-22

        The share price of Athenex Inc. (ATNX) is $0.01 (NASDAQ) as of 26-Jul-2023 09:30 EST. Athenex Inc. (ATNX) has given a return of -97% in the last 3 years.

        Athenex Inc. (ATNX) has a market capitalisation of $ 2 Mln as on 26-Jul-2023. As per Value Research classification, it is a Small Cap company.

        Since, TTM earnings of Athenex Inc. (ATNX) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Athenex Inc. (ATNX) and enter the required number of quantities and click on buy to purchase the shares of Athenex Inc. (ATNX).

        Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company's Orascovery product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company engages in developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinoma. Further, it engages in developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York. On May 14, 2023, Athenex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

        The CEO & director of Dr. Yiu-Nam Lau F.R.C.P., M.B.B.S., M.D., Ph.D.. is Athenex Inc. (ATNX), and CFO & Sr. VP is Mr. Jeffrey M. Yordon.

        The promoters of Athenex Inc. (ATNX) have pledged 0% of the total equity as on Jun-23.

        Some of the close peers are:

        Company Market Cap($ Mln)
        Athenex Inc. (ATNX) Ratios
        Return on equity(%)
        21.51
        Return on capital employed(%)
        27.21
        Debt-to-equity ratio
        -6.51
        Dividend yield(%)
        --

        No, TTM profit after tax of Athenex Inc. (ATNX) was $-69 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $2.33 Mln
        • Revenue (TTM)revenue-information $119.83 Mln
        • Earnings (TTM) earning-information $-69.25 Mln
        • Cash date-information $36.69 Mln
        • Total Debt info $42.36 Mln
        • Insider's Holding 9.73%
        • Liquidity liquidity
        • 52 Week range week-range $0.00 - 23.80
        • Shares outstanding share-outstanding 8,703,100
        • 9 Years Aggregate:

          CFO: $-730.45 Mln

          EBITDA: $-792.43 Mln

          Net Profit: $-971.90 Mln

        About The Company

        • IPO Date 14-Jun-2017
        • Chairman & CEO Dr. Yiu-Nam Lau F.R.C.P., M.B.B.S., M.D., Ph.D.
        • COO & Pres of Athenex Pharmaceutical Division Mr. Jeffrey M. Yordon
        • Listing key-listing NASDAQ: ATNX
        • Country United States
        • Headquarters headquarters Buffalo, NY
        • Website website https://www.athenex.com
        • Business

          Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company's Orascovery...  product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company engages in developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinoma. Further, it engages in developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York. On May 14, 2023, Athenex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.  Read more

        share-fund-plan-icon